Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: irasia.com
$23.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA advises Benitec Biopharma Ltd to proceed with Hepatitis C trial


Monday, 13 Jan 2014 05:32pm EST 

Benitec Biopharma Ltd:Says that the US Food and Drug Administration (FDA) has advised the company that it may proceed with its 'first in man' clinical trial for TT-034, a ddRNAi-based therapeutic, designed to treat Hepatitis C with a single injection.Says this follows the FDA's review of Benitec's Investigational New Drug (IND) application, which was filed on Dec. 6, 2013. 

Company Quote

0.97
-0.06 -5.83%
22 Sep 2014